Status:
UNKNOWN
3-year Immunogenicity Evaluation of Quadrivalent HPV Vaccine in China
Lead Sponsor:
Guangxi Center for Disease Control and Prevention
Conditions:
Anogenital Human Papilloma Virus Infection
Eligibility:
All Genders
9-45 years
Brief Summary
The thirty-six-month immunogenicity evaluation of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese female subjects aged 9 to 45 years and male subjects aged 9 to ...
Detailed Description
All eligible subjects will be enrolled for one visit. A medical history and physical examination will be conducted on all subjects. A 10 mL blood specimen will be collected. All Sera should be shipped...
Eligibility Criteria
Inclusion
- Healthy Chinese subject who participated in V501-030 in Per-protocol population.
- Subject agrees to provide study personnel with a primary telephone number as well as an alternate telephone number for follow-up purposes.
- Subject is willing to give consent/assent.
Exclusion
- Subject is concurrently enrolled in clinical studies of investigational agents which may interfere with the evaluation of the study objectives.
- Subject has any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives
- Subject has a history of known prior vaccination with a HPV vaccine, either active agent or placebo after receiving the vaccination during V501-030
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2012
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01427777
Start Date
September 1 2011
End Date
June 1 2012
Last Update
September 2 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Liuzhou CDC
Liuchow, Guangxi, China, 530028